medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2019, Number 05

<< Back Next >>

Ginecol Obstet Mex 2019; 87 (05)

Evaluation of the effect of the Prasterone in the treatment of hypoactive sexual desire in postmenopausal women

Hernández-Marín I, Villavicencio-Delgado A, Velázquez-Piña L

Language: Spanish
References: 9
Page: 288-294
PDF size: 364.10 Kb.


ABSTRACT

Objective: To determine the effects of the administration of 50 mg of DHEA orally daily on sexual function of menopausal patients.
Materials and Methods: We performed an experimental, clinical, prospective and longitudinal study in menopausal patients. We selected the sample from april to july 2017 with menopausal patients who attended for the first time at the clinic who met the inclusion criteria, having a final sample of 29 patients. Patients with a complete study protocol who met the entry criteria were administered 50 mg of prasterone (BiolaifTM) orally daily for 12 months, with a follow-up consultation every 3 months. Descriptive statistics were used for the statistical analysis. Also, Friedman’s two-dimensional analysis was used. All statistical studies were conducted in the SPSS program, v.22.
Results: Sexual Function Index evaluated with 29 patients at 6 months increased from an average of 10.8 to 28.1. At 12 months with 18 patients, after the treatment with 50 mg prasterone orally daily, it increased from an average of 10.6 to 29.1.
Conclusions: Sexual dysfunction is an underdiagnosed health problem in patients over the postmenopausal stage. Administration of prasterone (DHEA) at a dose of 50 mg orally daily improved the domains of Female Sexual Function Index of all our patients with statistically significant results, without side effects of hyperandrogenism.


REFERENCES

  1. Palacios S, et al. Epidemiology of female sexual dysfunction. Maturitas 2009;63(2):119-23. http://dx.doi.org/10.1016/j. maturitas.2009.04.002.

  2. Labrie F, et al. DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology. Frontiers in Neuroendocrinology 2001;22(3): 185-212. http://dx.doi.org/10.1006/frne.2001.0216

  3. Arlt W, et al. Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. J Clin Endocrinol Metab. 1998 Jun;83(6):1928-34. http://dx.doi. org/10.1210/jcem.83.6.4850

  4. Bouchard, C., et al. Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in posmenopausal women. Menopause 2009;16(5):923-31. http://dx.doi.org/10.1515/hmbci-2015-0044

  5. Davis SR, et al. DHEA replacement for posmenopausal women. JCEM 2011;96(6):1642-53. http://dx.doi.org/ 10.1210/jc.2010-2888.

  6. Elraiyah T. et al. The benefits and harms of systemic DHEA in posmenopausal women with normal adrenal function: a systematic review and meta-analysis. JCEM. 2014;99(10): 3536-42. http://dx.doi.org/10.1210/jc.2014-2261.

  7. Scheffers, C., et al. Dehydroepiandrosterone for women in the peri or posmenopausal phase. Cochrane Database of Systematic Reviews. http://dx.doi.org/10.1002/14651858.CD011066.

  8. Rosen, C. et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26(2):191- 208. http://dx.doi.org/ 10.1080/009262300278597.

  9. Sioba n D, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012;19(4):387-95. https://doi.org/10.1097/ gme.0b013e31824d8f40




2020     |     www.medigraphic.com